MOVE Stock Overview
Develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Medacta Group SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 108.40 |
| 52 Week High | CHF 135.00 |
| 52 Week Low | CHF 107.80 |
| Beta | 1.16 |
| 11 Month Change | -9.82% |
| 3 Month Change | -17.13% |
| 1 Year Change | -7.67% |
| 33 Year Change | -17.88% |
| 5 Year Change | 32.20% |
| Change since IPO | 12.80% |
Recent News & Updates
Is Medacta Group (VTX:MOVE) A Risky Investment?
Oct 14
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Sep 06What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Aug 21Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
Aug 06Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
Jun 20Recent updates
Is Medacta Group (VTX:MOVE) A Risky Investment?
Oct 14Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Sep 06What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Aug 21Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
Aug 06Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
Jun 20We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
May 01Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet
Apr 17Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Mar 29Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Feb 22Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around
Feb 07Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult
Dec 18Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Dec 04Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Nov 15Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
Oct 30If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
Oct 17Is Medacta Group (VTX:MOVE) Using Too Much Debt?
Sep 29Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Aug 11Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Jul 27Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital
Jul 03At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?
Apr 28Is Medacta Group (VTX:MOVE) A Risky Investment?
Apr 08Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Dec 25Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal
Dec 09Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Nov 09Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching
Sep 16The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence
Aug 20Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors
Jul 02Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?
May 28Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
May 12These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well
Mar 31Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Mar 17Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future
Feb 07Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?
Dec 10Medacta Group (VTX:MOVE) Knows How To Allocate Capital
Nov 05Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Sep 30Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?
Aug 26Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital
Jul 20Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?
May 19We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt
Apr 05What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition
Mar 02Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?
Feb 02The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More
Jan 12
Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture
Dec 21Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?
Dec 03Shareholder Returns
| MOVE | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | -5.4% | -3.1% | -1.4% |
| 1Y | -7.7% | 8.5% | 4.8% |
Return vs Industry: MOVE underperformed the Swiss Medical Equipment industry which returned 8.5% over the past year.
Return vs Market: MOVE underperformed the Swiss Market which returned 4.8% over the past year.
Price Volatility
| MOVE volatility | |
|---|---|
| MOVE Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 6.5% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: MOVE has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: MOVE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 1,826 | Francesco Siccardi | www.medacta.com |
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine procedures. Medacta Group SA was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
Medacta Group SA Fundamentals Summary
| MOVE fundamental statistics | |
|---|---|
| Market cap | CHF 2.24b |
| Earnings (TTM) | CHF 52.24m |
| Revenue (TTM) | CHF 505.83m |
41.4x
P/E Ratio4.3x
P/S RatioIs MOVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOVE income statement (TTM) | |
|---|---|
| Revenue | €544.29m |
| Cost of Revenue | €174.57m |
| Gross Profit | €369.72m |
| Other Expenses | €313.51m |
| Earnings | €56.21m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.82 |
| Gross Margin | 67.93% |
| Net Profit Margin | 10.33% |
| Debt/Equity Ratio | 54.1% |
How did MOVE perform over the long term?
See historical performance and comparison